Strides to get approx Rs 2.95 billion after Mylan's claims over Agila sale get rejected
Strides Pharma Science and its wholly-owned subsidiary completed the sale to Mylan Laboratories and Mylan Institutional of Agila Specialties Private Limited and Agila Specialties Global Pte Ltd in December 2013 for a total consideration of up to $1.75 billion.
New Delhi: Strides Pharma Science on Wednesday said it will receive $42 million (approx Rs 2.95 billion) from an escrow account after an international arbitration panel rejected US-based Mylan's claims over the sale of its injectables producer Agila Specialities Private to Mylan in 2013.
Strides Pharma Science and its wholly-owned subsidiary completed the sale to Mylan Laboratories and Mylan Institutional of Agila Specialties Private Limited and Agila Specialties Global Pte Ltd in December 2013 for a total consideration of up to $1.75 billion.
"Mylan made claims against the general claims escrow which included a third-party claim that was subject to resolution under international arbitration. The claims in that arbitration were rejected in their entirety.
"Strides will receive $42 million towards the full and final release of the general claims escrow immediately," Strides said in a regulatory filing.
Also Read: Strides Pharma board approves USD 15 million investment in Stelis Biopharma
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd